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Abstract
Inhibition of the  Ca2+-dependent proteases calpains attenuates post-infarction remodeling and heart failure. Recent data 
suggest that calpain activity is elevated in non-ischemic cardiomyopathies and that upregulation of the key cardiac G-pro-
tein-coupled receptor kinase 2 (GRK2) signaling hub promotes cardiac hypertrophy. However, the functional interactions 
between calpains and GRK2 in this context have not been explored. We hypothesized that calpain modulates GRK2 levels 
in myocardial hypertrophy of non-ischemic cause, and analyzed the mechanisms involved and the potential therapeutic 
benefit of inhibiting calpain activity in this situation. The oral calpain inhibitor SNJ-1945 was administered daily to male 
Sprague–Dawley rats or wild-type and hemizygous GRK2 mice treated with 5 mg/Kg/day isoproterenol intraperitoneally for 
1 week. In isoproterenol-treated animals, calpains 1 and 2 were overexpressed in myocardium and correlated with increased 
calpain activity and ventricular hypertrophy. Oral co-administration of SNJ-1945 attenuated calpain activation and reduced 
heart hypertrophy as assessed using morphological and biochemical markers. Calpain activation induced by isoproter-
enol increased GRK2 protein levels, while genetic downregulation of GRK2 expression prevented isoproterenol-mediated 
hypertrophy independently of calpain inhibition. GRK2 upregulation was associated to calpain-dependent degradation of 
the GRK2 ubiquitin ligase MDM2 and to enhanced NF-κB-dependent GRK2 gene expression in correlation with calpain-
mediated IĸB proteolysis. These results demonstrate that calpain mediates isoproterenol-induced myocardial hypertrophy by 
modulating GRK2 protein content through mechanisms involving the control of GRK2 stability and expression. Sustained 
calpain inhibition attenuates isoproterenol-induced myocardial hypertrophy and could be an effective therapeutic strategy 
to limit ventricular remodeling of non-ischemic origin.
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Introduction
Cardiac remodeling occurring in response to a variety of 
pathologic insults is causally associated with the progression 
of heart failure (HF) [35]. The limited efficacy of the current 
pharmacological treatments to prevent this adverse outcome 
reveals an urgent need for novel targets and strategies aimed 
to limit ventricular remodeling secondary to different insults.
Calpains are a family of  Ca2+-dependent cystein proteases 
that participate in basic  Ca2+-mediated processes [9]. Among 
all the calpain isoforms identified, calpain-1 and calpain-2 are 
ubiquitously expressed and regulated by the intracellular  Ca2+ 
concentration and by their endogenous inhibitor calpastatin. In 
pathological conditions associated with  Ca2+ overload, as in 
myocardial reperfusion, a deregulated calpain activation takes 
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place and contributes to myocardial injury through the prote-
olysis of different proteins [14].
In addition to its role in reperfusion injury, calpain-1 has 
been shown to participate in other situations resulting in ven-
tricular remodeling and HF. Transgenic overexpression of cal-
pain-1 in cardiomyocytes or restricted to mitochondria from 
cardiomyocytes, results in adverse remodeling and early mor-
tality even in the absence of significant variations in intracel-
lular  Ca2+ [4, 6]. Calpain-1 overexpression has been observed 
in different experimental models of HF including chronic myo-
cardial infarction and pressure overload induced by TAC or 
angiotensin II treatment [21, 36, 44], and in patients with con-
gestive HF [50]. However, although most studies using trans-
genic animals with altered calpain/calpastatin system suggest 
that calpain overexpression may play an important role in the 
development of myocardial remodeling during chronic stress 
[21, 26, 36, 51], the evidence is not consistent [31, 45, 48].
Recently, we have demonstrated that calpain inhibition 
starting 24 h after transient coronary occlusion attenuates 
adverse post-infarction remodeling independently of its car-
dioprotective effects during the acute phase of reperfusion 
by modulating the hypertrophic and fibrotic response to a 
transient coronary occlusion [34]. However, only a limited 
number of studies have examined whether pharmacological 
inhibition of calpains prevents cardiac remodeling caused by 
non-ischemic pathologic stimulus, and the precise mechanism 
involved has yet to be determined [31, 49].
The myocardial protein content of the G-protein-coupled 
receptor kinase 2 (GRK2), a critical regulator of the cardiac 
G-protein coupled receptor (GPCR) signaling, is increased in 
patients with HF and in animal models subjected to chronic 
stress [12, 28, 47], and genetic ablation of GRK2 has been 
associated to improved cardiac function and reduced adverse 
post-infarction remodeling [37, 42]. Furthermore, different 
studies using transgenic models suggest the participation 
of GRK2 in the regulation of the signaling pathways linked 
to cardiac hypertrophy induced by TAC, angiotensin II and 
β-adrenergic stimulation [42, 52]. Altogether, these previous 
data raise the possibility of an interaction between calpains and 
GRK2 during the development of hypertrophy.
Therefore, in the present study we have determined whether 
βAR/calpain/GRK2 signaling networks interact to induce ven-
tricular hypertrophy using a model of chronic stimulation of 
the β-adrenergic signaling with isoproterenol and tested the 
potential therapeutic efficacy of inhibiting calpains with a sus-
tained oral administration of a calpain inhibitor.
Methods
Experimental protocol
The experimental procedures conformed to the Guide 
for the Care and Use of Laboratory Animals published 
by the United States National Institute of Health (NIH 
Publication Eighth Edition, 2011), and were approved by 
the Research Commission on Ethics of the Hospital Vall 
d’Hebron.
Male Sprague–Dawley rats weighing 250–300 g were 
used in these experiments. Chronic β-adrenergic activa-
tion was achieved by administration of isoproterenol at a 
dose of 5 mg/kg given intraperitoneally daily for 7 days 
(ISO group). In a group of rats receiving isoproterenol, 
the calpain inhibitor SNJ-1945 (SENJU Pharmaceuti-
cal Co., Ltd.,120 mg/kg + 0.5% carboximethyl cellulose) 
was orally co-administered (ISO+SNJ group). In the 
control group, rats received an intraperitoneal injection 
of the saline vehicle and oral administration of 0.5% car-
boximethyl cellulose. After 7 days of treatment, animals 
were sacrificed by intraperitoneal dose of sodium pento-
barbital (100 mg/kg) and previous subcutaneous injec-
tion of buprenorphine (0.1 mg/kg). Hearts were excised, 
mounted in a Langendorff apparatus, perfused with Krebs 
buffer for blood removal and stored at − 80 °C or fixed in 
paraformaldehyde.
Male wild type (WT) and GRK2 hemizygous  (GRK2+/−) 
mice generated as previously described [25], were main-
tained on a C57BL/6 genetic background.  GRK2+/− and 
their corresponding WT littermates (10–12 weeks) were 
treated with isoproterenol with and without the co-admin-
istration of SNJ-1945 as described above.
Echocardiographic analysis
Transthoracic echocardiography was performed in rats at 
baseline and at the end of isoproterenol treatment using a 
Vivid Q portable ultrasound system equipped with a i12L-
RS 13 MHz transducer (GE Healthcare) as described ear-
lier [34]. The left ventricular end-systolic (LVESd) and 
diastolic (LVEDs) internal diameters, interventricular 
septum thickness at end diastole (IVS) and left ventricu-
lar posterior wall thickness at end diastole (LVPW) were 
measured in M-mode recordings. Ejection fraction (EF) 
was calculated according to standard formulas. Images 
were analyzed off-line by an investigator blinded to the 
groups. For each parameter, measurements were per-
formed from three to six different cardiac cycles, and the 
values were averaged.
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Histological measurements
Hearts were fixed in buffered 4% paraformaldehyde and 
embedded in paraffin for histological evaluation. Mean 
cardiomyocyte cross-sectional area was measured in trans-
verse sections stained with hematoxylin and eosin. At least 
50 random cells from each heart (n = 5–6 per group) were 
measured at 400 × magnification.
In vitro determination of calpain activity
Frozen myocardium was homogenized in ice-cold Tris-
buffered saline containing 1% Triton X-100 and centrifuged 
for 15 min at 15,000×g. Calpain activity was measured in 
the supernatant using the peptide substrate Suc-LLVY-
AMC (Calbiochem). The release of the fluorescent product 
AMC was quantified with a multilabel reader (excitation, 
360 nm; emission, 460 nm). The calpain inhibitor SNJ-1945 
(10 µmol/L) was used to determine the specificity of the 
assay.
RT‑PCR
Total RNA was extracted from heart samples using 
TRIsureTM reagent (BIOLINE, UK) following the manu-
facturer’s protocol. Quantitative RT-PCR was performed 
using Taqman universal PCR master mix (Applied Biosys-
tems, USA). The amplification program consisted of 50 °C 
for 2 min, 95 °C for 10 min and 40 cycles of 95 °C for 
15 s and 60 °C for 1 min and was performed in a 7900HT 
Fast Real-Time PCR System (Applied Biosystems, USA). 
Primers used for ANP, BNP, calpain-1, calpain-2, calpasta-
tin, Myh6, Myh7 and GADPH were purchased from Ther-
mofisher (Rn00561661_m1, Rn04219558_g1, Rn00569689_
m1, Rn00567422_m1, Rn00583952_m1, Rn00691721_g1, 
Rn01488777_g1 and Rn01775763_g1, respectively). For 
GRK2 self-designed probes were purchased from Sigma 
labeled with Syber Green (Table 1) and POWER SYBR 
Green PCR Master Mix (Applied Biosystems, USA) was 
used with an amplification program consisting in 94 °C for 
3 min, 40 cycles of 94 °C for 45 s, 55 °C for 30 s, 72 °C for 
1 min and 72 °C for 10 min.
Western blot analysis
Myocardial samples were homogenized and proteins sepa-
rated by SDS-PAGE for Western blot analysis as previ-
ously described [11]. Primary antibodies used were raised 
against calpain-1 (Calbiochem), calpain-2 (Abcam), cal-
pastatin (Abcam), CUL4A (Santa Cruz), DDB1 (Santa 
Cruz), Gβ (Santa Cruz), IĸB (Cell Signaling), MDM2 
(Santa Cruz), ERK1/2 (Santa Cruz), α-fodrin (Enzo), 
α-HMC (Abcam), α-SMA (Sigma-Aldrich), β-MHC 
(Abcam), GAPDH (Genetex) and Histone H3 (Abcam). 
GRK2 protein was detected with various specific rab-
bit polyclonal antibodies targeting different regions of 
the GRK2 (Fig. 4): AbFP2, raised against amino acids 
436–689 [29], Ab 792, raised against residues 533-544 
[7], and Ab C-15 (sc-562, Santa Cruz) that recognizes 
residues 675-689. GRK2 protein was normalized to total 
ERK1/2 levels. Protein bands were detected by chemilu-
miniscence (SuperSignal West Dura Extended Duration 
Substrate, Pierce) and quantified using a charge-coupled 
device system (Image Reader LAS-3000, Fujifilm) and 
image analysis software (Image Gauge, Fujifilm).
Analysis of MDM2 ubiquitination
Polyubiquitination levels of Mdm2 were analyzed using 
agarose-TUBEs (LifeSensors, Inc) following the manufac-
turer’s protocol. Pulled-down samples (50 mg of rat hearts) 
were analyzed by immunoblotting using the anti-MDM2 
antibody (N20 polyclonal rabbit 1:500, Santa Cruz) and 
then a specific polyubiquitin FK2 antibody (monoclonal 
1:500, Enzo).
Analysis of cardiac tissue‑polyubiquitinated GRK2
Frozen myocardium (80 mg) was homogenized and resolved 
in 7.5% non-reducing SDS-PAGE as previously described 
[40]. Ubiquitin conjugates of GRK2 were detected by immu-
noprecipitation of GRK2 protein with a monoclonal anti-
body (clone C5/1.1, Upstate) [40], followed by immunoblot-
ting with an anti-ubiquitin antibody (Sigma) that recognizes 
all forms of mono- and polyubiquitin chains conjugated to 
proteins. After stripping, blots were incubated with a specific 
anti-K48-linkage polyubiquitin antibody (Cell Signaling) to 
detect polyUb chains targeting GRK2 for degradation by the 
proteasome. Blots were reprobed with a rabbit-specific anti-
GRK2 antibody (sc-562, Santa Cruz) to detect total immu-
noprecipitated protein. Ubiquitination data were normalized 
by immunoprecipitated GRK2. Levels of GRK2 in whole-
tissue extracts of each experimental group were confirmed 
by Western blot using specific antibodies.
Table 1  Primers used for GRK2 RT-PCR analysis
BLDIS1 GRK2 Forward 5′-GGA TCG AGG AGA AGT GAC CTT-3′
Reverse 5′-TGG CCT CTT CCA GAT GGT T-3′
BIS2 GRK2 Forward 5′-CAT GCA CAA TCG CTT TGT AGTC-3′
Reverse 5′-AGG CCC AGG TCT GAG ATT C-3′
DIS1 GAPDH Forward 5′-TGC ACC ACC AAC TGC TTA GC-3′
Reverse 5′-TGG TCA TGA GCC CTT CCA C-3′
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Modulation of GRK2 transcriptional activity
We used human peripheral blood lymphocytes to investigate 
the modulation of GRK2 transcriptional activity. Peripheral 
blood T lymphocytes (PBTs) were obtained from buffy 
coats of healthy donors. The purity of the PBT popula-
tion was always higher than 95% CD3+ cells. When indi-
cated, cells were stimulated with the PKC activator Phorbol 
12-myristate 13-acetate (15 ng/mL, Sigma-Aldrich) and the 
 Ca2+ ionophore A23187 (1 µmol/L, Sigma-Aldrich). Viabil-
ity of the cells at the concentrations used was confirmed by 
the trypan blue dye exclusion test. Transcriptional activity 
was measured using a luciferase GRK2 promoter construct 
in the pGL3 basic reporter plasmid containing a 0.9 kb-long 
proximal region of the human GRK2 gene (pGRK2-0.9) 
[38]. The pGRK2-0.9 reporter construct was transfected 
in PBTs in the absence or presence of an IκBα pCDNA3 
expression plasmid [2], a generous gift of Dr J. Alcamí 
(CBMSO, Madrid). For transfection, cells were resuspended 
with 10 µg of plasmid DNA. In co-transfection experiments, 
0.5 µg/mL of the correspondent empty or expression plasmid 
was included. After electroporation, cells were cultured for 
16 h and then treated with different stimuli as indicated for 6 
h, harvested by centrifugation and lysed. Luciferase activity 
was determined using a luciferase assay kit (Promega) with 
a luminometer Monolight 2010 (Analytical Luminescence 
Laboratory). Transfection experiments were performed with 
PBTs from at least three different donors.
Statistical analysis
Data analysis was performed using SPSS for Windows. 
Mean values between groups were compared by one-way 
ANOVA. Least significant difference test was applied as 
post hoc test when significant differences were observed. 
Unpaired t test was used in Fig. 7c. Linear regression analy-
sis was used to analyze the correlation between mRNA lev-
els of calpain-1 and markers of hypertrophy in Fig. 2d. All 
results are expressed as mean ± SEM.
Results
Chronic isoproterenol induces myocardial calpain 
upregulation in rats
Calpain-1 and calpain-2 mRNA content was elevated in 
rats treated with isoproterenol (Fig.  1a) and correlated 
with increased protein content (70% and 46% vs. control 
group; Fig. 1b), with no significant effect of SNJ-1945 
treatment. The mRNA levels of calpastatin, the endogenous 
calpain inhibitor and also a calpain substrate were similar 
in all groups, while its protein levels were reduced in rats 
receiving isoproterenol but not in ISO + SNJ-treated animals 
(Fig. 1a, b). In agreement with such calpain and calpasta-
tin protein expression patterns, the maximal calpain activ-
ity measured in heart homogenates and the in situ calpain 
activity, evaluated by the presence of proteolytic fragments 
(145/150 kDa) of the calpain substrate α-fodrin, were ele-
vated in isoproterenol-treated rats (Fig. 1c). Importantly, oral 
administration of SNJ-1945 attenuated total calpain activity 
measured in vitro as well as α-fodrin and calpastatin degra-
dation (Fig. 1b–d), confirming the efficacy of the drug and 
route of administration in preventing calpain activation.
Oral, chronic administration of SNJ‑1945 attenuates 
isoproterenol‑induced hypertrophy
Acute mortality in the isoproterenol group reached 10%. 
After 1 week of isoproterenol administration, echocardiog-
raphy revealed cardiac hypertrophy as reflected by decreased 
ventricular internal dimensions and marked increase in LV 
posterior wall and septum thickness, heart weight/body 
weight ratio (Table  2 and Fig.  2a), and cardiomyocyte 
cross-sectional area (Fig. 2b). Daily oral co-administration 
of SNJ-1945 induced a significant attenuation in all these 
parameters. Providing further evidence of an isoproterenol-
induced hypertrophic phenotype that is counteracted upon 
calpain inhibition, the increased β-MHC/α-MHC ratio, ANP 
and BNP mRNA levels observed after isoproterenol admin-
istration were attenuated with sustained calpain inhibition 
(Fig. 2c). Conversely, these hypertrophic markers showed a 
linear correlation with calpain-1 mRNA levels upon chronic 
isoproterenol treatment (r2 = 0.88, p < 0.001 for β-MHC/α-
MHC ratio; r2 = 0.89, p < 0.001 for ANP, Fig. 2d).
Isoproterenol‑induced upregulation of GRK2 
protein content is prevented by calpain inhibition
Because GRK2 has been proposed to play a relevant role in 
cardiac hypertrophy, we next analyzed its protein levels in 
our different experimental groups using three antibodies tar-
geting different regions of the protein (Fig. 3a). After 7 days 
of isoproterenol administration, the protein expression pat-
terns detected by all the different antibodies showed a signif-
icant increase in myocardial GRK2 protein content that was 
prevented by sustained calpain inhibition (Fig. 3b). These 
data suggested that GRK2 upregulation might be a relevant 
hypertrophy-promoting event downstream isoproterenol-
stimulated calpain overactivation. Therefore, we evaluated 
the effects of isoproterenol administration and calpain inhi-
bition in previously characterized global hemizygous GRK2 
mice  (GRK2+/−) [25], and in their respective control litter-
mates (WT). In WT mice, chronic isoproterenol increased 
the heart weight/tibia length ratio as well as the β-HMC/
α-HMC ratio and ANP mRNA levels thus confirming 
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Ctrol    ISO    ISO+SNJ
Fig. 1  Chronic isoproterenol treatment induces calpain overexpres-
sion. a Cardiac mRNA levels of calpain-1, calpain-2 and calpastatin, 
b representative western blot and quantitative densitometric analysis 
of calpain-1, calpain-2, calpastatin protein levels and c 145/150-kDa 
α-fodrin fragments in the indicated control (C), isoproterenol (ISO) 
and isoproterenol + SNJ-1943 (ISO+SNJ)-treated experimental 
groups. d Maximal calpain activity measured in vitro using homoge-
nates obtained from hearts from the different experimental groups. 
SNJ: 10  µmol/L SNJ-1943 was added to homogenates from control 
hearts. Results are relative to GADPH, expressed as mean ± SEM. 
*p < 0.05 vs. control group, †p < 0.05 vs. ISO group. n = 4–6 per 
group
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myocardial hypertrophy (Fig. 4a–c). Calpain-1 was over-
expressed upon isoproterenol administration (Fig. 4d) and 
its inhibition with daily oral co-administration of SNJ-1945 
significantly attenuated hypertrophy (Fig. 4a–c), reinforcing 
our results obtained in rats. Notably, however, the genetic 
downregulation of GRK2 in  GRK2+/− animals markedly 
attenuated myocardial hypertrophy induced by isoproterenol 
and no additional effect was observed with the sustained 
inhibition of calpains (Fig. 4a–c). Interestingly, calpain-1 
remained upregulated in  GRK2+/− mice treated with isopro-
terenol, supporting the notion that GRK2 effects on hyper-
trophy are downstream calpain activation and that a calpain/
GRK2 axis plays a relevant role in isoproterenol-promoted 
hypertrophy.
Calpain activation upregulates GRK2 
by both decreasing its degradation machinery 
and by favoring its mRNA expression
GRK2 is a short-lived protein that undergoes polyubiqui-
tination and degradation by the proteasome [32, 33]. To 
determine whether calpain upregulates GRK2 by reducing 
its degradation, we analyzed the ability of purified calpain 
to degrade different E3 ubiquitin ligases present in myocar-
dial extracts that have been proposed to target GRK2 for 
proteolysis [32, 52], and whose potential downregulation 
by calpain would foster GRK2 stability. Our results showed 
a significant reduction in the protein levels of the MDM2 
ubiquitin ligase in myocardial samples exposed to activated 
calpains in in vitro conditions that was prevented by the 
inhibition of calpains (Fig. 5a). This pattern was similar to 
that observed for the cleavage of α-fodrin, used as a control 
of calpain activation. In contrast, calpain activation did not 
induce any significant change in the protein content of G 
protein subunit β  (Gβ), CUL4A or DDB1 (Fig. 5a). Impor-
tantly, calpain-dependent reduction in the levels of MDM2 
was also observed in myocardial samples obtained from 
isoproterenol-treated rats but not in those from rats receiv-
ing the co-administration of SNJ-1945 (Fig. 5b). Because 
MDM2 polyubiquitination by the ligase itself or by other 
factors can lead to increased MDM2 turnover [18], we next 
explored whether calpain activity might modulate MDM2 
protein stability in an ubiquitin-dependent manner. Endog-
enously polyubiquitinated proteins were specifically pulled 
down from cardiac extracts using the tandem ubiquitin-
binding entities (TUBEs) molecular tool, and probed with 
antibodies specific for MDM2. Of note, calpain inhibition 
prevented the increased MDM2 polyubiquitination observed 
in isoproterenol-treated animals (Fig. 6a). Overall, our data 
suggest that upon isoproterenol treatment, enhanced calpain 
activity might lead to decreased MDM2 levels via direct 
partial cleavage of MDM2 or by promoting the proteolytic 
clearance of unidentified MDM2 regulatory factors, result-
ing in increased polyubiquitination patterns of MDM2 and 
its degradation, while the presence of the calpain inhibitor 
prevents these events.
Consistent with the notion that MDM2 is key to promote 
ubiquitin-dependent degradation of GRK2, the polyubiqui-
tination status of GRK2 was notably reduced along with 
decreased Mdm2 levels in isoproterenol-treated hearts com-
pared to control samples, which display a strong signal of 
smeared bands in the 120–200 kDa range corresponding to 
polyubiquitinated GRK2 species, and this effect was attenu-
ated upon administration of the calpain inhibitor (Fig. 6b). 
Of note, isoproterenol treatment also promoted a decay in 
the levels of GRK2 with ubiquitin chains conjugated via 
lysine-K48 linkages (Fig. 6c), which is the chief ubiquit-
ination signal recognized by the proteasome and also the 
main ubiquitination pattern of myocardial GRK2 depend-
ing on MDM2 activity [17]. By contrast, calpain inhibition 
increased the extent of both high-order K48-ubiquitin GRK2 
(above 150 kDa) and of GRK2 species with two–three ubiq-
uitin moieties (circa 100 kDa) (Fig. 6c). Although the global 
levels of K48-polyubiquitinated GRK2 are similar in con-
trol conditions and in isoproterenol plus SNJ-1945-treated 
hearts (Fig. 6c), the patterns of K48-linked ubiquitin chains 
in the latter condition display species with low number of 
ubiquitin molecules (similar to those detected with antibod-
ies directed against bulk polyubiquitin-conjugated chains 
shown in Fig. 6b) that might be less efficiently degraded by 
the proteasome. Altogether, these results suggest that the 
upregulation of GRK2 induced by isoproterenol treatment 
involves a defective proteasomal degradation of this protein 
by the MDM2-ubiquitin axis.
To explore the possibility that calpain activation might 
also increase GRK2 protein levels by modulating its tran-
scription, myocardial GRK2 mRNA levels were measured 
Table 2  Weight and echocardiographic data
BW body weight, HW heart weight, HR heart rate, LVESD left ven-
tricular end-systolic diameter, LVEDD left ventricular end-diastolic 
diameter, LVPWT left ventricular posterior wall thickness, SWT sep-
tum wall thickness, EF ejection fraction
Mean ± SEM, *p < 0.05 vs. control group. †p < 0.05 vs. ISO group, 
analyzed by one-way ANOVA with LSD test
Control (n = 6) ISO (n = 9) ISO+SNJ (n = 8)
BW (g) 332 ± 12.5 336.2 ± 13.8 330.1 ± 8.8
HW (g) 1.07 ± 0.02 1.38 ± 0.02* 1.18 ± 0.04*†
HW/BW × 100 0.33 ± 0.02 0.41 ± 0.01* 0.36 ± 0.01†
HR (bpm) 342 ± 17 362 ± 12 348 ± 9
LVESD (mm) 3.9 ± 0.12 2.77 ± 0.14* 3.47 ± 0.24†
LVEDD (mm) 7.29 ± 0.16 6.01 ± 0.17* 6.71 ± 0.18*†
LVPWT (mm) 1.81 ± 0.12 2.78 ± 0.12* 2.30 ± 0.12*†
SWT (mm) 1.60 ± 0.09 2.66 ± 0.05* 2.17 ± 0.15*†
EF (%) 82.33 ± 1.92 78.46 ± 2.32 85.47 ± 2.25
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Fig. 2  Oral SNJ-1945 treatment attenuates isoproterenol-induced 
cardiac hypertrophy. a Hearts from the different experimental 
groups were analyzed for: heart weight/body weight ratio (HW/BW) 
and increase in septum (∆SWT) and posterior wall (∆PWT) thick-
ness (n = 5–8 rats per group); b ventricular cross-sections from these 
hearts were stained with hematoxylin and eosin followed by quantifi-
cation of cardiomyocyte cross-sectional area (50 random cells/heart, 
n = 5–6 hearts per group). Representative images shown. c mRNA 
β-MHC/mRNA α-MHC ratio and mRNA levels of ANP and BNP 
were normalized with respect to the control group (n = 5–6 hearts per 
group). Results are presented as mean ± SEM. *p < 0.05 vs. control 
group. †p < 0.05 vs. ISO group. d Linear correlation between mRNA 
levels of calpain-1 and markers of hypertrophy (mRNA β-MHC/
mRNA α-MHC ratio and ANP mRNA), n = 5–6 hearts per group
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using two different primers. We found that isoproterenol 
treatment significantly enhances GRK2 gene expression 
while the co-administration of the calpain inhibitor pre-
vents this effect (Fig. 7a). In search of potential mechanisms 
underlying such isoproterenol-induced and calpain-mediated 
increase in GRK2 mRNA levels, we noted that the 5′-flank-
ing region of the proximal GRK2 human gene promoter con-
tains consensus sequences for putative response elements 
of the NFĸB transcription factors (Fig. 7b). Interestingly, 
activation of this nuclear factor has been related to isopro-
terenol-induced cardiac hypertrophy [5], and suggested to 
regulate the transcription of the GRK5 isoform in myocytes 
[16], whereas IĸB, which restricts the activation of the 
NFĸB pathway, is a known calpain substrate [34]. Thus, we 
explored the modulation of the transcriptional activity of the 
human GRK2 promoter by the NFĸB pathway by expressing 
a luciferase reporter construct in human peripheral blood 
lymphocytes as a suitable heterologous experimental system. 
GRK2 expression in human peripheral lymphocytes mirrors 
changes in myocardial GRK2 levels during HF [13], and 
it has been proposed to have prognostic value in patients 
with HF [39]. Cell treatment with a combination of stimuli 
known to trigger NFĸB stimulation [27], triggered a marked 
induction of GRK2 human promoter activity, which was 
significantly inhibited by co-transfection of the inhibitory 
construct IĸBα (Fig. 7c), consistent with a role for the NFĸB 
cascade in GRK2 transcription. In line with these data, we 
found that myocardial IĸB is proteolysed when exposed to 
activated calpains in vitro (Fig. 7d) and that a significant 
calpain-dependent degradation of IĸB is observed in myo-
cardial extracts of rats upon chronic isoproterenol treatment 
(Fig. 7e), strongly suggesting a functional link between 
NFĸB activity and GRK2 expression in this context.
Discussion
The present study proposes calpain-dependent upregulation 
of GRK2 protein levels, through both reduced degradation 
and increased synthesis, as a new mechanism of myocardial 
hypertrophy induced by chronic isoproterenol administra-
tion, and suggests that pharmacological calpain inhibition 
may prevent cardiac remodeling of non-ischemic cause.
Increasing evidence demonstrates that calpains are 
involved in cardiac remodeling occurring in response to 
chronic stress [22, 31, 49]. Previous studies using animal 
models with reduced calpain activity, by deletion of calpains 
1 and 2 [26], or overexpression of calpastatin [51], have 
reported attenuated ventricular remodeling and dysfunction 
in experimental models with permanent coronary occlusion, 
while enhancing calpain activity by deletion of calpastatin 
had the opposite effect [20]. In contrast to post-infarction 
remodeling, the evidence supporting the contribution of 
calpains to cardiac remodeling in other common pathologic 
models of HF is more controversial. Overexpression and 
activation of calpain-1 have been described in myocardial 
samples from patients with congestive HF [49, 50] and 
in mice and rats subjected to aortic constriction [36, 49], 
receiving chronic administration of angiotensin II [21] or 
isoproterenol [3, 49]. However, although calpain inhibition 
by forced overexpression of calpastatin reduced angioten-
sin-induced myocardial and perivascular inflammation and 
fibrosis [21], it has been associated with the development 
of dilated cardiomyopathy [6]. Furthermore, while the use 
of a non-specific calpain inhibitor suggested the contribu-
tion of calpains to isoproterenol-induced hypertrophy [1], 
A 
B 
533       544  
Ab 792
675      689 
Ab sc C-15
436                                689 
Ab PF2
















 Ctrol  ISO ISO+SNJ  Ctrol  ISO ISO+SNJ   Ctrol  ISO  ISO+SNJ





Fig. 3  Isoproterenol-induced upregulation of GRK2 protein content 
is prevented by calpain inhibition. a Myocardial extracts from con-
trol, ISO, and ISO+SNJ-treated rats were partially enriched in GRK2 
protein for immunoblotting and analyzed using different antibodies 
raised against the indicated GRK2 regions. b Results were normal-
ized to total ERK1/2 and expressed as fold change compared to con-
trol (n = 3–4 per group). A representative blot is shown. Data are pre-
sented as mean ± SEM. *p < 0.05 vs. ISO group
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cardiac-specific knockout of the subunit Capn4, shared by 
calpain-1 and calpain-2, increased ventricular remodeling 
and dysfunction in mice subjected to either chronic isopro-
terenol treatment or TAC [45].
Despite the evidence on the pathophysiological impor-
tance of calpains in ventricular hypertrophy, there is a lack 
of studies testing the potential of pharmacological calpain 
inhibition as a therapeutic strategy for the treatment of ven-
tricular remodeling [31, 49]. In our study we analyzed the 
effect of oral administration of SNJ-1945, a third-generation 
calpain inhibitor designed to improve its water solubility and 
bioavailability [30], in the cardiac hypertrophy induced by 
chronic administration of the β-agonist isoproterenol. Sus-
tained adrenergic activity in the myocardium has been impli-
cated in the development of pathological hypertrophy and 
progression of HF in animal models and humans [23]. In our 
study, and in agreement with previous reports, isoproterenol 
at 5 mg/Kg/day for 1 week, induced cardiac hypertrophy 
without producing significant cardiac dysfunction [41]. In 
this model we observed calpain activation associated to an 
increased expression of calpain-1 and calpain-2, with a close 
correlation between the expression of hypertrophic markers 
and calpain-1.
Importantly, daily oral administration of SNJ-1945 
effectively inhibited myocardial calpain activity and 
markedly attenuated cardiomyocyte hypertrophy in both 
rats and mice. Although it has been suggested that some 
calpain inhibitors also inhibit MMP-2, which shares pro-
tein targets with calpain, previous results from our group 
exclude the possibility that the effects on hypertrophy 
obtained with SNJ-1945 were consequence of MMP-2 
inhibition [34].
Different studies demonstrate that GRK2 is overexpressed 
in models subjected to chronic stress [12, 28, 47], and par-
ticipates in the development of myocardial remodeling. In 
this regard, genetic inhibition of GRK2 activity prevented 
hypertrophy in response to TAC or β-adrenergic stimulation 
[42, 52]. In line with these studies, our results show that 
isoproterenol increases GRK2 protein levels. More impor-
tantly, sustained calpain inhibition prevented upregulation 
of GRK2, while the hemizygous deletion of GRK2 markedly 
attenuated myocardial hypertrophy induced by isoproterenol 
without altering calpain expression. Overall, these results 
strongly suggest that GRK2 upregulation is a relevant event 
in cardiac hypertrophy downstream isoproterenol-induced 
calpain overactivation.
Fig. 4  Calpain contributes to 
isoproterenol-induced hyper-
trophy by upregulating GRK2 
protein content. a heart weight/
tibia length ratio (HW/TL), b 
mRNA β-MHC/mRNA α-MHC 
ratio, c mRNA levels of ANP 
and d mRNA levels of cal-
pain-1, in wild type (WT) and 
GRK2 hemizygous  (GRK2+/−) 
mice receiving vehicle (C), or 
isoproterenol (ISO) with and 
without the co-administration 
of SNJ-1945 (ISO+SNJ group). 
mRNA levels are normalized 
with respect to WT control 
(C) group (n = 4–5 hearts per 
group). Results are presented 
as mean ± SEM. *p < 0.05 vs. 
control group. †p < 0.05 vs. ISO 
group
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We found that calpain-dependent upregulation of GRK2 
protein levels involves mechanisms affecting both its deg-
radation and synthesis (Fig. 8). GRK2 has been shown to 
be rapidly degraded by the proteasome pathway. Compel-
ling evidence demonstrates that MDM2 is the main E3 
ligase implicated in the ubiquitination and degradation 
of GRK2 upon GPCR activation [32, 40]. Our data show 
that isoproterenol treatment promotes a calpain-depend-
ent decrease in cardiac MDM2 levels. The suitability of 
MDM2 as a calpain substrate is supported by the presence 
in the protein sequence of the E3 ligase of two canonical 
PEST sequences [15], which are regulatory determinants 
for calpain-mediated degradation of many proteins, and 
by a previous report suggesting that calpains participate 
in the downregulation of MDM2 in the epidermis after UV 
irradiation [8]. In addition, our data suggest that calpain 
activity might modulate MDM2 protein stability by pro-
moting the proteolytic clearance of unidentified MDM2 
regulatory factors, resulting in increased polyubiquitina-
tion patterns of MDM2 and its degradation. On the other 
hand, it has been described that  Gβ binds to DDB1 and tar-
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Fig. 5  Isoproterenol-induced calpain activation reduces myocar-
dial MDM2 protein levels. a Myocardial rat extracts were incubated 
with recombinant calpain 1 with and without SNJ1945 for 0, 15, 30 
and 60 min and analyzed for potential calpain-mediated cleavage of 
MDM2, Gβ, DDB1, and CUL4A by western blot. Calpain-dependent 
α-fodrin cleavage was used as a control. b MDM2 content in myo-
cardial extracts obtained from control (Ctrol), isoproterenol (ISO) 
and isoproterenol + SNJ-1943 (ISO + SNJ) treated rat groups (n = 5 
hearts per group) was assessed by western blot. Results are presented 
as mean ± SEM. *p < 0.05 vs. control group. Representative western 
blots are shown in both panels
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Fig. 6  Calpain inhibition decreases the extent of Mdm2 polyubiqui-
tination and enhances polyubiquitination of GRK2 in isoproterenol-
treated rats. a Polyubiquitination levels of Mdm2 in cardiac lysates 
from the indicated experimental conditions were analyzed using 
affinity-TUBEs pull-downs. Mdm2 bands were normalized to their 
corresponding ubiquitin smears and ratios were normalized to ubiq-
uitinated Mdm2 level in control samples. b The same cardiac lysates 
used in panel C were analyzed for global GRK2 ubiquitination or, c 
specific (K)-48-linked polyubiquitination. The extent of both param-
eters inversely correlates with the total levels of GRK2 protein, d 
determined in these cardiac lysates by immunoblotting with a spe-
cific GRK2 antibody and normalized by tubulin as loading control. In 
panels a–d data indicate the mean ± SEM, n = 2–4 mice for each con-
dition. Representative western blots are shown in all panels. Arrow-
heads indicate polyubiquitinated forms of ~ 100 Kda [Ub(3)-GRK2] 
and above (see text for details). *p < 0.05 vs. control group. †p < 0.05 
vs. ISO group
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E3 ligase complex [52]. The same group proposed that 
isoproterenol stabilizes GRK2 via a PKA-dependent 
reduction in the association between  Gβ and the DDB1-
CUL4A complex. However, although our results do not 
rule out the participation of this cascade by indirect ways, 
the levels of these potential regulators were not affected 
by calpain overactivation, pointing instead to MDM2 as 
the downstream factor underlying isoproterenol-induced 
upregulation of GRK2 protein. Consistent with this notion, 
the extent of bulk and of specific (K)-48-linked GRK2 
polyubiquitination inversely correlated with the total lev-
els of GRK2 protein in isoproterenol and isoproterenol 
plus calpain inhibitor-treated rat groups, in coherence with 
the patterns of MDM2 expression in those groups. On the 
other hand, it is intriguing that myocardial GRK2 is not 
proteolytically processed by active calpains in conditions 
of chronic isoproterenol treatment, despite its reported 
partial degradation by calpain-2 in other cellular con-
texts [24]. Cardiac hypertrophy signaling pathways may 


















Ctrol                        PMA+Ion
















Ctrol    ISO  ISO+SNJ           Ctrol    ISO  ISO+SNJ
































Ctrol    ISO    ISO+SNJ
* 
E 







0      15    30    60  60/SNJ  
D 






Fig. 7  Isoproterenol-induced calpain activation increases GRK2 
gene expression by cleaving IĸB. a Quantification of mRNA lev-
els of GRK2 using two different primers (n = 5 per group) in rat 
hearts obtained from the indicated experimental groups. Data are 
mean ± SEM. *p < 0.05 vs. control group. †p < 0.05 vs. ISO group. 
b Scheme of the proximal 5´-flanking region of the human GRK2 
gene promoter. Putative cis-acting consensus sequences for NFκB 
transcription factors are detailed and their relative position denoted 
by boxes. c Involvement of the NFκB pathway in the induction of 
GRK2 promoter activity. Human peripheral blood lymphocytes were 
co-transfected with the pGRK2-0.9 luciferase promoter construct 
plus an empty vector or an expression vector for the IκBα protein. 
Transfected cells were treated with PMA plus the Ca2 + Ionophore 
A23187. Luciferase activity is expressed as RLUs ± SEM. Similar 
results were obtained with cells from three different donors. *p < 0.01 
vs. corresponding control group. d Myocardial rat extracts were incu-
bated with recombinant calpain 1 with and without SNJ1945 for 0, 
15, 30, and 60 min and analyzed for calpain-mediated IĸB cleavage 
as in Fig.  5a. e IĸB content in myocardial extracts obtained from 
control (Ctrol), isoproterenol (ISO) and isoproterenol + SNJ-1943 
(ISO+SNJ)-treated rat groups (n = 5 hearts per group) was assessed 
by western blot. Data are mean ± SEM. *p < 0.05 vs. control group. 
†p < 0.05 vs. ISO group. Representative western blots are shown in 
panels d and e 
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triggering “protective” GRK2 post-transcriptional modi-
fications or by keeping away GRK2 from active calpains.
In sum, we propose that the calpain-dependent degra-
dation of MDM2 would contribute to the enhanced GRK2 
levels in isoproterenol-treated hearts as a result of increased 
GRK2 stabilization. Endogenous GRK2 levels increase in 
mouse embryonic fibroblasts lacking MDM2 [40], whereas 
both global or cardiomyocyte-specific deletion of MDM2 
in mice led to a significant increase in cardiac GRK2 lev-
els [17]. Importantly, conditional cardiomyocyte MDM2 
deletion results in severely impaired cardiac function and 
decreased beta-adrenergic receptor responsiveness, which 
could be rescued upon delivery of a GRK2 inhibitor [17]. 
suggesting a relevant role for the MDM2/GRK2 regulatory 
axis in heart function. In this line, other studies have associ-
ated the downregulation of MDM2 with the development of 
cardiac hypertrophy induced by phenylephrine or endothe-
lin-1 [46].
Our results also demonstrate that isoproterenol upregu-
lates the synthesis of GRK2 by a calpain-dependent tran-
scriptional mechanism. Although transcriptional upregu-
lation of GRK2 and GRK5 isoforms has been reported 
in several cardiovascular pathologies, including hypertro-
phy, the underlying mechanisms have not been explored 
in detail. Our data put forward the NFĸB cascade as a 
relevant calpain-dependent axis for enhancing GRK2 
mRNA levels upon chronic isoproterenol treatment. NFκB 
activation in human lymphocytes, a bona fide model for 
changes in cardiomyocyte GRK2 expression [39], pro-
motes a marked increase in the transcriptional activity 
of the proximal GRK2 promoter, which displays several 
canonical binding sites for this factor, whereas the pres-
ence of extra IκB significantly attenuates it.
On the other hand, the NFκB regulator IκB is a well-
known calpain substrate and its calpain-dependent deg-
radation has been associated to the activation of NFĸB 
and the development of post-infarction remodeling [26, 
34]. Our data demonstrate that calpain activation induced 
by chronic isoproterenol treatment also reduces myocar-
dial IĸB levels. Altogether, these results suggest a novel 
mechanism involved in the regulation of myocardial GRK2 
expression in which calpain activation results in IκB pro-
tein degradation, in turn leading to NFκB activation and 
upregulation of GRK2 expression (Fig. 8).
The NFĸB signaling pathway has been shown to play 
a critical role in the regulation of cardiac GRK5 expres-
sion at the level of gene transcription, promoting stress-
induced GRK5 upregulation [16], and treatment of aortic 
vascular smooth cells with PMA reportedly increased the 
mRNA content of GRK2 [38], suggesting that the NFκB 
pathway might be a common trigger for maladaptive 
enhanced expression of cardiovascular GRKs, although 
regarding GRK2 the participation of other transcription 
factors downstream the isoproterenol/calpain axis cannot 
be ruled out.
A large amount of evidence suggests that NFκB plays a 
key role in cardiac hypertrophy induced by chronic stress 
[10, 19], and this nuclear factor has been related to isoproter-
enol-induced cardiac hypertrophy and remodeling [5]. The 
expression of a mutant IκB that acts as a super-repressor of 
NFκB in transgenic mice-attenuated hypertrophy induced 
by isoproterenol or angiotensin II infusion [5]. Since it has 
been proposed that GRK2 can activate NFκB and induce 
maladaptative hypertrophy [43], it is tempting to suggest 
that myocardial GRK2 and NFκB activity may co-regulate 
each other to trigger hypertrophic gene transcriptional acti-
vation. Upregulation of cardiac calpains [34] and GRK2 [12] 
and calpain-dependent activation of NFκB [34] have also 
been described during post-infarction remodeling. Hence, 
our results strongly suggest that the calpain/GRK2 axis may 
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Fig. 8  Calpain activation modulates myocardial GRK2 protein levels 
by mechanisms affecting both its degradation and synthesis. Chronic 
isoproterenol treatment results in calpain activation which contributes 
to myocardial hypertrophy by upregulating GRK2 protein content. In 
the one hand, calpain reduces the levels of MDM2 thus increasing the 
stability of GRK2. In the other hand, calpain cleavages IĸB therefore 
activating NFĸB which in turn increases GRK2 gene transcription. 
Oral administration of SNJ-1945 is an effective strategy to prevent 
these effects
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The fact that calpains are overactivated in response to 
numerous stimuli associated to the development of hyper-
trophy suggests that calpain activation is a general response 
of cardiomyocytes to chronic stress. Despite that, pharma-
cological calpain inhibition has barely been considered as a 
therapeutic strategy for the treatment of ventricular remod-
eling [49]. Our study shows that sustained calpain inhibition 
is a promising novel treatment for preventing the develop-
ment of hypertrophy. Although either oral or intraperitoneal 
administration of SNJ-1945 for 14 days produced no obvious 
toxicity or abnormalities in rats [30, 34], longer term and 
more detailed analysis of side effects are needed.
In conclusion, our study shows that chronic isoproterenol 
administration induces calpain overexpression and activa-
tion, which contributes to isoproterenol-induced myocardial 
hypertrophy by mechanisms involving GRK2 upregulation. 
Furthermore, our results unveil novel mechanisms affect-
ing the regulation of myocardial GRK2 levels (Fig. 8). The 
present data demonstrate that the role of calpains in ven-
tricular hypertrophy goes beyond post-infarction remod-
eling and suggest that sustained pharmacological inhibition 
of calpains may be an effective strategy to limit myocardial 
hypertrophy induced by chronic stress of both ischemic and 
non-ischemic origin.
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